A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Tirasemtiv (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms VIGOR-ALS
- Sponsors Cytokinetics
- 06 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Nov 2017 According to a Cytokinetics media release, the company will seek advice from the academic leadership of VITALITY-ALS and its clinical investigators, regulatory authorities and other consultants before making decisions about continuing treatment with tirasemtiv in VIGOR-ALS.
- 02 Aug 2017 According to a Cytokinetics media release, the company expects to continue to enroll patients who complete VITALITY-ALS study into VIGOR-ALS throughout 2017.